Table 3.
rMBC characteristic comparisons by diagnosis year (n = 964)
| 1990–2011 | 1990–1998 | 1999–2004 | 2005–2011 | p value | |
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | ||
| Number of patients | 964 (100%) | 455 (47%) | 260 (27%) | 249 (26%) | |
| Age at initial diagnosis (years) | 54 (23–93) | 54 | 55 | 54 | 0.217 |
| Stage at initial diagnosis | |||||
| I | 163 (17%) | 87 (19%) | 47 (18%) | 29 (12%) | 0.002 |
| II | 447 (46%) | 218 (48%) | 126 (49%) | 103 (41%) | |
| III | 354 (37%) | 150 (33%) | 87 (34%) | 117 (47%) | |
| Hormone receptor status | |||||
| Positive | 703 (74%) | 335 (75%) | 191 (74%) | 177 (71%) | 0.512 |
| HER2 status* (n = 475) | |||||
| Positive | 80 (16%) | 49 (21%) | 31 (13%) | 0.012 | |
| HR/HER2 status* (n = 475) | |||||
| HR+/HER2− | 287 (60%) | 138 (60%) | 149 (61%) | 0.011 | |
| HR+/HER2+ | 53 (11%) | 29 (13%) | 24 (10%) | ||
| HR−/HER2- | 108 (23%) | 43 (19%) | 65 (27%) | ||
| HR−/HER2+ | 27 (6%) | 20 (9%) | 7 (3%) | ||
| First recurrence | |||||
| Local/regional | 78 (8%) | 41 (9%) | 17 (7%) | 20 (8%) | 0.002 |
| Distant | 790 (82%) | 381 (84%) | 221 (85%) | 188 (76%) | |
| Local/regional/distant | 96 (10%) | 33 (7%) | 22 (9%) | 41 (17%) | |
| Number of metastases | |||||
| 1 | 573 (59%) | 290 (64%) | 159 (61%) | 124 (50%) | 0.001 |
| 2+ | 391 (41%) | 165 (36%) | 101 (39%) | 125 (50%) | |
| Dominant site of distant metastases | |||||
| Bone | 328 (35%) | 170 (39%) | 100 (39%) | 58 (24%) | < 0.001 |
| Visceral | 522 (56%) | 218 (50%) | 141 (55%) | 163 (67%) | |
| Soft tissue | 87 (9%) | 48 (11%) | 15 (6%) | 24 (10%) | |
| Distant disease-free interval (mean years) | 5.03 (0.17–24.48) | 5.64 (0.46–24.48) | 5.16 (0.39–16.92) | 3.80 (0.17–11.95) | < 0.001 |
*Trastuzumab FDA approval 1998, consistent HER2 testing began in 1999